Stocks in Action USA: Exelixis, Fiserv, Rezolve AI
Reading Time: 4 minutes
Exelixis (EXEL) achieves breakthrough in colorectal cancer research with new drug combination! The biotechnology company Exelixis has generated attention with the announcement of initial results from its pivotal Phase 3 study STELLAR-303. The investigation showed that a combination of the company’s own tyrosine kinase inhibitor Zanzalintinib and the immunotherapy Atezolizumab (Tecentriq) significantly improves the survival time of patients with metastatic, non-MSI-high colorectal cancer – compared to the previous standard therapy with Regorafenib....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
